EU approves AZ’ Bydureon BCise device
AstraZeneca says the European Commission has approved a new formulation of its once-weekly diabetes drug Bydureon.
According to the firm, Bydureon BCise (exenatide extended release) is an improved single-dose, pre-filled pen device that requires no titration.
It is approved for use in combination with other glucose-lowering medicines, including basal insulin, to help improve glycaemic control in adults with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise.
Read more: http://www.pharmatimes.com/news/eu_approves_az_bydureon_bcise_device_1250738
According to the firm, Bydureon BCise (exenatide extended release) is an improved single-dose, pre-filled pen device that requires no titration.
It is approved for use in combination with other glucose-lowering medicines, including basal insulin, to help improve glycaemic control in adults with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise.
Read more: http://www.pharmatimes.com/news/eu_approves_az_bydureon_bcise_device_1250738